Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
September 8th, 2023
2K views
The increase of molecular biomarkers to be tested for non-squamous non-small cell lung cancer (NS-NSCLC) care management has prompted the development of fast and reliable molecular detection methods. We describe a workflow for genomic alteration assessment for NS-NSCLC patients using an ultra-fast-next generation sequencing (NGS) approach.
Overview
This study addresses the urgent need for rapid detection of genomic alterations in non-squamous non-small cell lung cancer (NS-NSCLC) to inform targeted therapies. An ultra-fast next-generation sequencing (NGS) workflow is presented as a solution for efficient analysis of small biopsy samples.
Key Study Components
Research Area
- Oncology
- Molecular diagnostics
- Next-generation sequencing
Background
- Targeted therapies for NS-NSCLC depend on timely detection of genomic alterations.
- Traditional biopsy methods often yield small samples, complicating analysis.
- A comprehensive approach for rapid testing is needed to enhance patient care.
Methods Used
- Ultra-fast next-generation sequencing (NGS)
- Analysis of formalin-fixed paraffin-embedded (FFPE) samples
- Automated purification and sequencing processes
Main Results
- The workflow identifies key genetic mutations and fusions in a time-efficient manner.
- High sensitivity for detecting various genomic alterations was achieved.
- Comprehensive molecular profiling was performed on 259 NS-NSCLC patients.
Conclusions
- This study demonstrates a new standard for rapid genomic profiling in NS-NSCLC.
- It provides critical insights for personalized treatment strategies in oncology.
Frequently Asked Questions
What are the advantages of the ultra-fast NGS workflow?
The ultra-fast NGS workflow allows for rapid detection of genetic mutations in small biopsy samples, minimizing the time to diagnosis and treatment.
How many patients were analyzed in this study?
A total of 259 patients with non-squamous non-small cell lung cancer were included in the analysis.
What sample types were used for this analysis?
The study utilized various biopsy types and surgical specimens, including formalin-fixed paraffin-embedded (FFPE) tissues.
What are the implications of this research for lung cancer treatment?
The findings support the development of rapid genomic profiling methods that can inform targeted therapy decisions, improving patient outcomes.
What methodologies are compared in this study?
The study compares traditional molecular testing methods, such as RT-PCR and fluorescence in situ hybridization, with the proposed NGS approach.
What is the primary goal of the proposed NGS workflow?
The primary goal is to enable timely and comprehensive genomic profiling for optimal therapy selection in NS-NSCLC patients.
Executive Industry Relevance
Ultra-fast amplicon-based next-generation sequencing (NGS) enables rapid, comprehensive molecular profiling of non-squamous non-small cell lung cancer (NS-NSCLC) from small and diverse biopsy samples. This capability addresses the increasing demand for timely detection of actionable genomic alterations, supporting precision therapy selection and reducing diagnostic delays. Integrating such workflows at the diagnostic inflection point enhances predictive confidence and portfolio decision-making in thoracic oncology.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables robust identification of clinically actionable genomic alterations in NS-NSCLC.
- Supports functional target validation by detecting driver mutations and gene fusions.
- Facilitates biological de-risking through comprehensive molecular characterization.
- Improves predictive confidence for downstream therapeutic hypothesis testing.
Screening & Assay Development
- Delivers standardized, reproducible molecular profiling suitable for high-throughput diagnostic workflows.
- Provides quantitative outputs for SNVs, INDELs, CNVs, and fusions, supporting assay readiness.
- Reduces tissue consumption and turnaround time, enabling efficient sample triage.
- Prepares validated molecular data for integration into screening and biomarker platforms.
Translational & Preclinical Research
- Aligns molecular profiling with translational biomarker strategies in thoracic oncology.
- Ensures continuity from diagnostic discovery to preclinical model selection and validation.
- Supports risk-adjusted advancement decisions by providing comprehensive genomic data.
- Enables mechanistic de-risking for novel therapy development in NS-NSCLC.
Pipeline & Workflow Integration
This ultra-fast NGS workflow bridges diagnostic discovery and translational research, supporting rapid lead identification and preclinical validation in NS-NSCLC portfolios.
- Discovery Biology: Accelerates hypothesis testing and pathway clarification by enabling multiplexed genomic analysis.
- Screening: Provides reproducible, quantitative molecular outputs for assay development and compound evaluation.
- Analytics: Generates detailed variant, fusion, and copy number data for cross-condition comparison and decision support.
- Translational Research: Facilitates biomarker alignment and preclinical model selection based on real-world tumor genomics.
- Enterprise Reuse: Establishes a scalable, automated platform for ongoing molecular profiling across diverse sample types.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target selection.
- Operational Value: Standardizes and accelerates molecular diagnostics with minimal tissue requirements.
- Strategic Value: Enables faster go/no-go decisions and optimizes resource allocation in oncology pipelines.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of targeted therapy candidates.
Implementation Considerations
- Requires expertise in molecular pathology and NGS data interpretation.
- Depends on automated instrumentation and integrated genomic analysis software.
- Demands cross-team standardization for sample processing and data reporting.
- Must adapt protocols for varying sample sizes and tissue types, including cytological specimens.
- Turnaround time and sensitivity are influenced by sample quality and input material limitations.
Biopharma FAQs
Why does null hypothesis testing matter for NGS-based target validation?
Null hypothesis testing in NGS workflows ensures that detected genomic alterations are statistically significant and not due to background noise, supporting confident target validation in NS-NSCLC. This statistical rigor underpins reliable identification of actionable mutations for therapy selection. It reduces the risk of false positives in portfolio decision-making.
How does independent variable isolation fit the NGS discovery pipeline?
Isolating independent variables, such as specific gene mutations or fusions, allows the workflow to attribute observed molecular changes directly to actionable targets. This clarity supports mechanistic de-risking and informs downstream therapeutic hypothesis testing. It streamlines the transition from discovery to clinical application.
What do quantitative dependent variable measurements enable in NGS analysis?
Quantitative measurements of SNVs, INDELs, CNVs, and fusions enable precise comparison across samples and conditions, supporting robust assay development and biomarker discovery. These outputs facilitate reproducibility and scalability in diagnostic and translational research. They provide actionable data for cross-functional R&D teams.
Why are replication requirements critical for cross-functional NGS collaboration?
Replication ensures that molecular findings are consistent across different sample types and runs, supporting confidence in diagnostic and translational outputs. This reliability is essential for cross-team integration and portfolio advancement decisions. It underpins standardization in enterprise-scale molecular diagnostics.
What statistical analysis capabilities are required before NGS implementation?
Robust statistical analysis is needed to validate sensitivity, specificity, and reproducibility of detected variants in the NGS workflow. These capabilities ensure that only clinically relevant alterations inform therapy selection and pipeline progression. They are foundational for regulatory and operational acceptance in biopharma R&D.
Chapters in this video
0:00
Introduction
2:11
Preparation of FFPE DNA and RNA Samples for Sequencing Using Automated Purification Instrument (API)
4:42
Amplicon‐Based Next‐Generation Sequencing of Non‐Squamous Non‐Small Cell Lung Cancer
5:50
Sequencing Analysis of Non‐Squamous Non‐Small Cell Lung Cancer Using Integrated Genomic Viewer Software
